Assembly Biosciences, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Assembly Biosciences, Inc. (ASMB) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$12.36 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-09
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$12.36M.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$78.28M, a 242.89% decline year-over-year.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $65.56M.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$12.74M.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$40.56M, a 175.88% decline from fiscal 2017.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $53.46M, a 3544.04% increase from fiscal 2016.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.47M.
- Assembly Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$1.98M, a 197.72% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 69 month | Cash and Cash Equivalents, Period Increase (Decrease) 72 month | Cash and Cash Equivalents, Period Increase (Decrease) 75 month | Cash and Cash Equivalents, Period Increase (Decrease) 78 month | Cash and Cash Equivalents, Period Increase (Decrease) 81 month | Cash and Cash Equivalents, Period Increase (Decrease) 84 month | Cash and Cash Equivalents, Period Increase (Decrease) 87 month | Cash and Cash Equivalents, Period Increase (Decrease) 90 month | Cash and Cash Equivalents, Period Increase (Decrease) 93 month | Cash and Cash Equivalents, Period Increase (Decrease) 96 month | Cash and Cash Equivalents, Period Increase (Decrease) 99 month | Cash and Cash Equivalents, Period Increase (Decrease) 102 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | -$12.36M 10-Q · filed 2019-05-09 | -$90.65M derived: sum of 2 quarters · filed 2019-05-09 | -$25.08M derived: sum of 3 quarters · filed 2019-05-09 | -$37.82M derived: sum of 4 quarters · filed 2019-05-09 | ||||||||||||||
| 2018-12-31 | -$78.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$12.72M derived: sum of 2 quarters · filed 2019-02-28 | -$25.46M derived: sum of 3 quarters · filed 2019-02-28 | -$40.56M 10-K · filed 2019-02-28 | ||||||||||||||
| 2018-09-30 | $65.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $52.83M derived: sum of 2 quarters · filed 2018-11-08 | $37.72M 10-Q · filed 2018-11-08 | $92.50M derived: sum of 4 quarters · filed 2019-05-09 | ||||||||||||||
| 2018-06-30 | -$12.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$27.84M 10-Q · filed 2018-08-08 | $26.94M derived: sum of 3 quarters · filed 2019-05-09 | $14.74M derived: sum of 4 quarters · filed 2019-05-09 | ||||||||||||||
| 2018-03-31 | -$15.11M 10-Q · filed 2019-05-09 | -$15.11M 10-Q · filed 2018-05-07 | $39.68M derived: sum of 2 quarters · filed 2019-05-09 | $27.47M derived: sum of 3 quarters · filed 2019-05-09 | -$3.89M derived: sum of 4 quarters · filed 2019-05-09 | |||||||||||||
| 2017-12-31 | $54.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $42.58M derived: sum of 2 quarters · filed 2019-02-28 | $11.22M derived: sum of 3 quarters · filed 2019-02-28 | $53.46M 10-K · filed 2019-02-28 | $53.46M 10-K · filed 2018-03-08 | |||||||||||||
| 2017-09-30 | -$12.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$43.57M derived: sum of 2 quarters · filed 2018-11-08 | -$1.33M 10-Q · filed 2018-11-08 | $3.45M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||||
| 2017-06-30 | -$31.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $10.88M 10-Q · filed 2018-08-08 | $15.66M derived: sum of 3 quarters · filed 2019-02-28 | $19.11M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||||
| 2017-03-31 | $42.24M 10-Q · filed 2018-05-07 | $47.02M derived: sum of 2 quarters · filed 2019-02-28 | $50.48M derived: sum of 3 quarters · filed 2019-02-28 | $50.42M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||||
| 2016-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $8.23M derived: sum of 2 quarters · filed 2019-02-28 | $8.18M derived: sum of 3 quarters · filed 2019-02-28 | $1.47M 10-K · filed 2019-02-28 | $1.47M 10-K · filed 2017-03-02 | |||||||||||||
| 2016-09-30 | $3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $3.40M derived: sum of 2 quarters · filed 2017-11-01 | -$3.31M 10-Q · filed 2017-11-01 | -$12.61M derived: sum of 4 quarters · filed 2018-03-08 | ||||||||||||||
| 2016-06-30 | -$53.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$6.77M 10-Q · filed 2017-08-09 | -$16.06M derived: sum of 3 quarters · filed 2018-03-08 | -$33.18M derived: sum of 4 quarters · filed 2018-03-08 | ||||||||||||||
| 2016-03-31 | -$6.71M 10-Q · filed 2017-05-08 | -$16.01M derived: sum of 2 quarters · filed 2018-03-08 | -$33.12M derived: sum of 3 quarters · filed 2018-03-08 | -$75.66M derived: sum of 4 quarters · filed 2018-03-08 | ||||||||||||||
| 2015-12-31 | -$9.29M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$26.41M derived: sum of 2 quarters · filed 2018-03-08 | -$68.95M derived: sum of 3 quarters · filed 2018-03-08 | -$1.98M 10-K · filed 2018-03-08 | ||||||||||||||
| 2015-09-30 | -$17.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$59.65M derived: sum of 2 quarters · filed 2016-11-09 | $7.31M 10-Q · filed 2016-11-09 | $18.47M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||||||||
| 2015-06-30 | -$42.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $24.43M 10-Q · filed 2016-08-09 | $35.59M derived: sum of 3 quarters · filed 2017-03-02 | $32.20M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||||||||
| 2015-03-31 | $66.96M 10-Q · filed 2016-05-10 | $78.12M derived: sum of 2 quarters · filed 2017-03-02 | $74.74M derived: sum of 3 quarters · filed 2017-03-02 | $72.42M derived: sum of 4 quarters · filed 2017-03-02 | ||||||||||||||
| 2014-12-31 | $11.16M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $7.77M derived: sum of 2 quarters · filed 2017-03-02 | $5.45M derived: sum of 3 quarters · filed 2017-03-02 | $2.03M 10-K · filed 2017-03-02 | ||||||||||||||
| 2014-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$5.70M derived: sum of 2 quarters · filed 2015-11-09 | -$9.13M 10-Q · filed 2015-11-09 | -$14.29M derived: sum of 4 quarters · filed 2015-11-09 | ||||||||||||||
| 2014-06-30 | -$2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$5.74M 10-Q · filed 2015-08-13 | -$10.91M derived: sum of 3 quarters · filed 2015-08-13 | -$12.17M derived: sum of 4 quarters · filed 2015-08-13 | ||||||||||||||
| 2014-03-31 | -$3.42M 10-Q · filed 2015-05-08 | -$8.59M derived: sum of 2 quarters · filed 2015-05-08 | -$9.85M derived: sum of 3 quarters · filed 2015-05-08 | -$13.24M derived: sum of 4 quarters · filed 2015-05-08 | $23.64M 10-Q · filed 2014-05-14 | |||||||||||||
| 2013-12-31 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$6.43M derived: sum of 2 quarters · filed 2015-03-16 | -$9.81M derived: sum of 3 quarters · filed 2015-03-16 | $6.57M 10-K · filed 2015-03-16 | $27.06M 10-K · filed 2014-03-31 | |||||||||||||
| 2013-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-17 | -$4.65M derived: sum of 2 quarters · filed 2014-11-17 | $11.73M 10-Q · filed 2014-11-17 | $8.66M derived: sum of 4 quarters · filed 2014-11-17 | $32.22M 10-Q · filed 2013-11-12 | |||||||||||||
| 2013-06-30 | -$3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $13.00M 10-Q · filed 2014-08-14 | $9.93M derived: sum of 3 quarters · filed 2014-08-14 | $4.65M derived: sum of 4 quarters · filed 2014-08-14 | $33.49M 10-Q · filed 2013-08-09 | |||||||||||||
| 2013-03-31 | $16.38M 10-Q · filed 2014-05-14 | $13.31M derived: sum of 2 quarters · filed 2014-05-14 | $8.03M derived: sum of 3 quarters · filed 2014-05-14 | $5.81M derived: sum of 4 quarters · filed 2014-05-14 | $36.87M 10-Q · filed 2013-05-10 | |||||||||||||
| 2012-12-31 | -$3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | -$8.35M derived: sum of 2 quarters · filed 2014-03-31 | -$10.58M derived: sum of 3 quarters · filed 2014-03-31 | -$16.49M 10-K · filed 2014-03-31 | $20.49M 10-K · filed 2013-03-18 | |||||||||||||
| 2012-09-30 | -$5.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$7.51M derived: sum of 2 quarters · filed 2013-11-12 | -$13.42M 10-Q · filed 2013-11-12 | -$29.73M derived: sum of 4 quarters · filed 2013-11-12 | $23.56M 10-Q · filed 2012-11-13 | |||||||||||||
| 2012-06-30 | -$2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$8.13M 10-Q · filed 2013-08-09 | -$24.45M derived: sum of 3 quarters · filed 2013-08-09 | $17.48M derived: sum of 4 quarters · filed 2013-08-09 | $28.84M 10-Q · filed 2012-08-09 | |||||||||||||
| 2012-03-31 | -$5.91M 10-Q · filed 2013-05-10 | -$22.23M derived: sum of 2 quarters · filed 2013-05-10 | $19.70M derived: sum of 3 quarters · filed 2013-05-10 | $17.07M derived: sum of 4 quarters · filed 2013-05-10 | $31.07M 10-Q · filed 2012-05-09 | |||||||||||||
| 2011-12-31 | -$16.32M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $25.61M derived: sum of 2 quarters · filed 2013-03-18 | $22.97M derived: sum of 3 quarters · filed 2013-03-18 | $22.40M 10-K · filed 2013-03-18 | $36.98M 10-K · filed 2012-03-14 | |||||||||||||
| 2011-09-30 | $41.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $39.29M derived: sum of 2 quarters · filed 2012-11-13 | $38.72M 10-Q · filed 2012-11-13 | $53.02M derived: sum of 4 quarters · filed 2013-03-18 | $53.29M 10-Q/A · filed 2011-11-18 | |||||||||||||
| 2011-06-30 | -$2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$3.20M 10-Q · filed 2012-08-09 | $11.10M derived: sum of 3 quarters · filed 2013-03-18 | $10.72M derived: sum of 4 quarters · filed 2013-03-18 | $11.37M 10-Q · filed 2011-08-15 | |||||||||||||
| 2011-03-31 | -$570.53K 10-Q · filed 2012-05-09 | $13.73M derived: sum of 2 quarters · filed 2013-03-18 | $13.35M derived: sum of 3 quarters · filed 2013-03-18 | |||||||||||||||
| 2010-12-31 | $14.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-03-18 | $13.92M derived: sum of 2 quarters · filed 2013-03-18 | $14.49M 10-K · filed 2013-03-18 | |||||||||||||||
| 2010-09-30 | -$378.65K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2011-11-18 | $189.79K 10-Q/A · filed 2011-11-18 | ||||||||||||||||
| 2010-06-30 | $568.44K 10-Q · filed 2011-08-15 | |||||||||||||||||
| 2009-12-31 | $65.44K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |